Peer-reviewed veterinary case report
Better photodynamic therapy for horse sarcoids using glycolysis
By Golding, J. P. et al.·Published in Veterinary and Comparative Oncology·2017·School of Life, Health and Chemical Sciences The Open University Milton Keynes UK, United Kingdom·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Glycolysis inhibition improves photodynamic therapy response rates for equine sarcoids
- Species:
- horse
Plain-English summary
A group of horses with different types of skin tumors called sarcoids were treated with a new method combining a photosensitizer and a glycolysis inhibitor. The treatment involved applying a special solution to help the photosensitizer penetrate the skin, followed by a glycolysis inhibitor to enhance the effectiveness of the therapy. After one month, 93% of the sarcoids showed improvement with this new treatment, compared to only 14% improvement with the standard method. This suggests that the new approach could be a more effective option for treating equine sarcoids.
People also search for: horse sarcoid treatment · equine skin tumor therapy · photodynamic therapy for horses
Abstract
Photodynamic therapy (PDT) holds great promise in treating veterinary and human dermatological neoplasms, including equine sarcoids, but is currently hindered by the amount of photosensitiser and light that can be delivered to lesions thicker than around 2 mm, and by the intrinsic antioxidant defences of tumour cells. We have developed a new PDT technique that combines an efficient transdermal penetration enhancer solution, for topical delivery of 5‐aminolevulinic acid (ALA) photosensitiser, with acute topical post‐PDT application of the glycolysis inhibitor lonidamine. We show that the new PDT combination treatment selectively kills sarcoid cells in vitro, with repeated rounds of treatment increasing sarcoid sensitisation to PDT. In vivo, ALA PDT followed by 600 μM lonidamine substantially improves treatment outcomes for occult, verrucous, nodular and fibroblastic sarcoids after 1 month (93% treatment response in 27 sarcoids), compared with PDT using only ALA (14% treatment response in 7 sarcoids).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12299